Real-World ES-SCLC Findings Analogous With IMpower133 Results
Eric Nadler, MD, MPP, discusses the real-world patient characteristics and treatment duration of the immunotherapy combination treatment studied in the IMpower133 trial in extensive-stage small cell lung cancer.
Eric Nadler, MD, MPP, the medical director of Health Informatics and Internet Technology for The US Oncology Network and an oncologist at Texas Oncology, discusses the real-world patient characteristics and treatment duration of the immunotherapy combination treatment studied in the IMpower133 trial (NCT02763579) in extensive-stage small cell lung cancer (ES-SCLC).
According to Nadler, the real-word treatment duration data are very similar to the IMpower133 study of atezolizumab (Tecentriq) in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. The real-world population did not have extended follow-up data, due to the recency of approval.
The similarity remains even when taking into account that the real-world population tends to be older and sicker than the clinical trial population, according to Nadler. One in 4 patients in the real-world cohort had an ECOG status of 3 or higher and were a little older than the clinical trial population. Additionally, almost a quarter of patients in the real-world had brain metastases, compared to the just under 10% in the trial population.
